Designed to provide broad exposure to the Large Cap Growth segment of the US equity market, the First Trust NASDAQ-100 Ex-Technology Sector ETF (QQXT) is a passively managed exchange traded fund ...

We will be sharing Q1 2025 hedge fund investor letters in this article. You can also see the hedge fund investor letters for 2024 Q4, 2024 Q3, 2024 Q2 , 2024 Q1, 2023 Q4, 2023 Q3 and 2023 Q2 by ...

Vertex Pharmaceuticals has multiple growth drivers with potentially more on the way. Yo-yos are fun for kids. But yo-yo stock ...

Aristotle Atlantic’s Core Equity Composite posted a total return of -5.90% gross of fees (-5.99% net of fees). Read more here.

Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...

If you're interested in broad exposure to the Large Cap Growth segment of the US equity market, look no further than the First Trust NASDAQ-100 Equal Weighted ETF (QQEW), a passively managed exchange ...

We recently published a list of 12 Best Tech Stocks to Buy For Long-Term Investment. In this article, we are going to take a ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

On CNBC's “Halftime Report Final Trades ,” Joshua Brown of Ritholtz Wealth Management picked CrowdStrike Holdings, Inc. CRWD.

The recent tumult on Wall Street is beginning to create price dislocations, which is what a value-focused investor like ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won approval for a non-opioid pain ...

Vertex Pharmaceuticals slipped 1.41% to close at $475.49, managing to outperform a much gloomier market where the S&P 500 nose-dived 3.46%. Despite the drop, Vertex flexed its resilience, outpacing ...